art news

01/02/2010
Arterial Remodeling Technologies receives ISO 13485 certification
Certification comes on the heels of data published in EuroIntervention Journal special supplement

ISO 13485 is an internationally recognized medical device Quality Management System (QMS) standard developed by the International Organization for Standardization (ISO). To be certified to the standard, companies must implement a medical device QMS ensuring that steps have been taken to identify, manage and minimize the risks involved with the manufacturing and use of its medical devices. Certification to ISO 13485 reinforces through an independent third-party that ART operates its medical device QMS in accordance with the recognized standard.

See complete article

04/01/2010
ART reports its bioresorbable stent platform restores the remodeling capacity of arterial walls
Data published in EuroIntervention Journal special supplement

Arterial Remodeling Technologies ("ART") announced today that it has disclosed impressive in vivo and in vitro data related to its bioresorbable stent platform-data that validates the Company's approach to simultaneously balance biocompatibility, biomechanics and bioresorption in a bioresorbable PLA (polylactic acid) stent without altering healing by drug elution from the stent platform.

See complete article

04/11/2008
Chief Executive Officer
Paris, November 2008

Arterial Remodeling Technologies (“ART”) announced today that it has appointed Machiel Van Der Leest as its Chief Executive Officer, effective immediately.
Most recently,Van Der Leest was ART’s Chief Operating Officer since March 2008. Prior to joining ART, he was Director of R&D and Regulatory Affairs since May 2003 at Minvasys.

Prior to Minvasys,Van Der Leest was Director of R&D for Cathnet-Science (Nycomed Amersham Medical Systems, or “NAMS”, until July 2000) from Sept. 1999 through May 2003.
He is trilingual (English, French, Dutch) and received a MSc degree in Industrial Design Engineering from the Technical Univ. Delft, Netherlands, in 1996.

E-mail : mvanderleest@art-stent.com

16/07/2008
ART's Article Published in VIVO
Published July 6, 2008

Many industry executives believe bioabsorbable devices may be the next big thing in coronary stents after drug-eluting stents. Most bioabsorbable stent companies are hedging their bets, combining drug elution with stents that disappear. Not ART, who's betting that natural healing beats drug therapy.

See complete article

Website : www.windhover.com/article

E-mail : dcassak@windhover.com

Author : David Cassak

09/06/2008
Interview of Dr. Lafont
Vanishing Stents - Part 2

What if there were a stent that could promote natural remodeling of an injured artery after angioplasty, and then just disappear? "Just three years ago bioresorbable stents seemed to be more of a nice to have than a need to have.
After all, drug-eluting stents (DES) were seen as the answer to restenosis and showed very minimal risks to patient safety. Johnson & Johnson and Boston Scientific had the clear lead in introducing Cypher and Taxus, respectively, to the interventional community, with Medtronic, Guidant, and Abbott Laboratories bringing up the rear. Then in September 2006 at the World Congress of Cardiology meeting...DES were linked to a four-letter word delivering a new danger corporate executives once again began asking a question they thought they had answered: why deploy a permanent implant on a short-term mission of clearing a coronary artery?" (Source: 'Bioabsorbable Stents', Start-Up, January 2007) In part two of “Vanishing Stents”, we again consider Paris-based ARTERIAL REMODELING TECHNOLOGIES ("ART"). ART's stent is designed to provide the requisite initial acute mechanical scaffolding, but, as it dismantles due to bioresorbability, the possibility of arterial remodeling returns to the artery. Our expert is Antoine Lafont, MD, PhD, Professor of Medicine at the University of Paris; Head of Interventional Cardiology at Georges Pompidou Hospital in Paris; and, Chairman of the Interventional Cardiology Group of the European Society of Cardiology (ESC). Dr. Lafont is a co-founder of ART.

See the interview